New method for toxicological assessment of perfluoro mixtures Perfluoro (PFAS) is a group of substances that contains PFOS, PFOA and GenX. Perfluoro substances often occur as pollution in ground water and drinking water.
Disease burden and cost-of-illness of food-related pathogens in the Netherlands Each year, RIVM presents an update on the number of illnesses caused by 14 enteric pathogens (such as Salmonella, Campylobacter or Listeria) that can be transmitted by food into the human body.
Animal-free innovations in safety assessment of chemicals How can the process of validation, acceptance and use of animal-free innovative approaches to assess the safety of chemicals be facilitated?
RIVM measures much higher levels of tar, nicotine and carbon monoxide in cigarettes Tar, nicotine and carbon monoxide (TNCO) levels measured in accordance with the Canadian Intense (CI) method are at least twice as high as the levels measured in accordance with the prescribed ISO
Addictive nicotine and harmful substances also present in heated tobacco Heated tobacco products are newly available on the market. An example of such a product is the heatstick which is heated with an iQOS, a device that looks like an e-cigarette.
RIVM withdraws from tobacco committees The Dutch National Institute for Public Health and the Environment will leave the NEN/CEN/ISO committees for tobacco and e-cigarettes with immediate effect.
Chance of ESBL contamination via livestock farming is small ESBL is an enzyme, produced by certain bacteria, which makes these bacteria resistant to antibiotics.
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Proposal for water quality standards for PFOA RIVM proposes water quality standards for perfluoro octanoic acid (PFOA). PFOA is a man-made chemical that is used to protect surfaces.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.